Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share in line with the Zacks Consensus Estimate. This compares to loss of$1.04 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.97 per share when it actually produced a loss of$0.05, delivering a surprise of 94.85%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Arcus Biosciences, which belon ...